Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Rangering i aksjer #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Aksjekurs
$0.03702159
Sist synkronisert: 2024-01-29
Markedsverdi
$7.21M
Endring (1 dag)
-3.08%
Endring (1 år)
0.00%
Land
AU
Handel Antisense Therapeutics Limited (ANP)

Kategori

Historikk for aksjesplitt for Antisense Therapeutics Limited (ANP)
Aksjen Antisense Therapeutics Limited (symbol: ANP) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 17, 2026.
Én ANP-aksje kjøpt før Aug 17, 2026 tilsvarer i dag 0 ANP-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter